Current opinion on aspirin in primary prevention of atherosclerotic cardiovascular diseases. Is there any difference between diabetic and non-diabetic patients?
2013
Abstrakt
Aspirin reduces vasculardeath by approximately 15% and nonfatal vascular events by about 30% in secondary prevention. The evidence in primary prevention in non-diabetic subjects is not so powerful.
The benefit of aspirin primary prevention in type 2 diabetes remains to be advocated definitely.